Valuation: Evotec SE

Capitalization 1.17B 1.34B 1.1B 996M 1.84B 116B 2.07B 12.93B 4.99B 52.93B 5.02B 4.91B 195B P/E ratio 2025 *
-14.3x
P/E ratio 2026 * -36.5x
Enterprise value 1.33B 1.53B 1.25B 1.14B 2.1B 133B 2.37B 14.76B 5.7B 60.42B 5.73B 5.61B 223B EV / Sales 2025 *
1.56x
EV / Sales 2026 * 1.45x
Free-Float
88.77%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.40%
1 week-13.58%
Current month-5.52%
1 month-6.28%
3 months+0.12%
6 months-21.01%
Current year-19.85%
More quotes
1 week 6.57
Extreme 6.568
7.48
1 month 6.57
Extreme 6.568
8.57
Current year 5.06
Extreme 5.06
9.33
1 year 5.06
Extreme 5.06
10.62
3 years 5.06
Extreme 5.06
29.71
5 years 5.06
Extreme 5.06
45.83
10 years 2.86
Extreme 2.864
45.83
More quotes
Manager TitleAgeSince
Chief Executive Officer - 2024-06-30
Director of Finance/CFO - 2025-02-28
Chief Tech/Sci/R&D Officer 61 2010-08-31
Director TitleAgeSince
Chairman 64 2021-06-14
Director/Board Member 57 2019-06-18
Director/Board Member 63 2021-05-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-4.12%-13.58%-10.46%-71.62% 1.34B
-0.29%-4.35%+17.87%+12.23% 48.12B
-0.45%-8.53%+63.51%+91.43% 29.99B
-18.96%+293.44%+58,645.35%+5,549.30% 31.33B
+0.33%-2.84%-27.36%-21.50% 26.75B
-1.29%-2.26%-4.61%+18.91% 25.65B
-1.75%-1.62%+13.39%-19.28% 12.25B
-1.48%-3.03%+127.74% - 11.96B
+1.11%-2.49%-54.99%-28.60% 11.41B
-1.27%-0.12%+38.57%+103.42% 10.31B
Average -2.26%+25.52%+5,880.90%+626.03% 20.91B
Weighted average by Cap. -3.27%+40.48%+8,802.06%+900.33%
See all sector performances

Financials

2025 *2026 *
Net sales 853M 978M 801M 728M 1.34B 84.92B 1.51B 9.45B 3.65B 38.69B 3.67B 3.59B 142B 939M 1.08B 882M 802M 1.48B 93.55B 1.67B 10.41B 4.02B 42.62B 4.04B 3.96B 157B
Net income -81.21M -93.13M -76.29M -69.38M -128M -8.09B -144M -900M -348M -3.69B -350M -342M -13.57B -29.86M -34.24M -28.05M -25.51M -47.03M -2.97B -53.06M -331M -128M -1.35B -128M -126M -4.99B
Net Debt 165M 189M 155M 141M 260M 16.43B 293M 1.83B 706M 7.49B 710M 695M 27.58B 200M 229M 188M 171M 315M 19.92B 355M 2.22B 856M 9.08B 861M 842M 33.43B
More financial data * Estimated data
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,766
More about the company
Date Price Change Volume
25-06-20 6.714 +2.22% 134,645
25-06-19 6.568 -4.12% 499,686
25-06-18 6.850 -2.14% 1,128,616
25-06-17 7.000 -1.69% 701,920
25-06-16 7.120 -3.76% 992,098

Delayed Quote Xetra, June 19, 2025 at 11:40 am EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.568EUR
Average target price
11.32EUR
Spread / Average Target
+72.43%
Consensus

Quarterly revenue - Rate of surprise